Loading
HKSEHealthcareBiotechnology
Latest quote
HK$3.795
−HK$0.015 · -0.39%
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Latest quote
HK$3.795
−HK$0.015 · -0.39%
Regular session · HKT · Market data may be delayed.
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Day range
Current HK$3.795
52-week range
Current HK$3.795
Regular session · HKT · Market data may be delayed.
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Day range
Current HK$3.795
52-week range
Current HK$3.795
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 747.65M CNY | 1.1B CNY | 780.63M CNY | 442.18M CNY | 76.33M CNY |
| Cost of goods sold | 358.67M CNY | 315.9M CNY | 206.64M CNY | 71.56M CNY | 48.85M CNY |
| Gross profit | 388.98M CNY | 782.43M CNY | 573.99M CNY | 370.62M CNY | 27.47M CNY |
| Research and development | 85.68M CNY | 79.31M CNY | 103.89M CNY | 151.17M CNY | 214.7M CNY |
| Selling, general, and administrative | 401.58M CNY | 688.09M CNY | 509.33M CNY | 266.54M CNY | 79.19M CNY |
| Operating expenses | 479.67M CNY | 741.18M CNY | 607.05M CNY | 409.45M CNY | 287.17M CNY |
| Interest income | 2.25M CNY | 3.38M CNY | 2.97M CNY | 2.27M CNY | 969K CNY |
| Interest expense | 11.92M CNY | 9.88M CNY | 5.18M CNY | 6.6M CNY | 2.47M CNY |
| Depreciation and amortization | 74.05M CNY | 38.8M CNY | 43.03M CNY | 38.04M CNY | 34.24M CNY |
| Operating income | −90.69M CNY | 41.25M CNY | −33.06M CNY | −39.08M CNY | −259.7M CNY |
| Net income | −100.37M CNY | 34.76M CNY | −37.76M CNY | −49.92M CNY | −261.22M CNY |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
